HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained a $10 price target.
April 23, 2024 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reiterates a Buy rating on BioXcel Therapeutics with a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards BioXcel Therapeutics. This endorsement suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100